Description
Global Stem Cell Therapy Market Forecast till 2027
Market Overview
The stem cell therapy market is expected to attain a significant CAGR of 10.74% during the review period of 2020 to 2027.
Stem cell therapy is used to cure any disease. The global market growth is attributed to the rising prevalence of chronic diseases, expanding healthcare industry, and the growing expenditure on medical research. Additionally, the increasing number of clinical studies for stem cell therapy are fuelling the global market growth during the review period.
The global stem cells therapy market is expected to register a healthy market expansion during the forecast period owing to the largest market value of USD 5,735.12 million in 2020.
Moreover, an increment in the number of clinical investigations for stem cell therapy is, driving the market development. In any case, the moral worries identified with early-stage stem cell-based treatments and the related significant expenses might hamper the stem cell therapy market development in the future.
Market Segmentation
The stem cell therapy market has been classified in terms of cell source, type, application, and end-user.
Based on cell source the market is classified into adipose tissue, bone marrow, embryo/cord blood-derived, neural, IPSCs, and PSCs.
Based on type, the stem cell therapy market is divided into allogenic and autologous.
By application, the market is classified into diabetes, musculoskeletal disorders, cancer, cardiovascular disorders, gastrointestinal diseases, and others.
In terms of end-user, the global market is categorized into hospitals & clinics, academic research centers, and others.
Regional Analysis
Geographically the stem cell therapy market is spread across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The expanded public-private financing and exploration awards for delivering protected and successful stem cell therapy items and the presence of central members in the locale are the main considerations driving America’s stem cell therapy market.
Europe holds the second biggest portion of the overall industry because of an increment in the eagerness of patients to go through stem cell therapy and a developing number of instances of persistent and neurological problems.
Asia-Pacific is the quickest developing territorial market for stem cell treatments as it is growing quickly and has seen the rise of numerous players. In addition, the rising pervasiveness of disease, and developing reception of stem cell therapy medicines in the area, are probably going to drive the market’s development.
The stem cell therapy market in the Middle East& Africa is relied upon to observe confined development because of an absence of public mindfulness and restricted reasonableness among the populace. Be that as it may, some regenerative medication applications are occurring in the Gulf nations.
Major Players
The key companies listed in the stem cell therapy market report Seraxis, Inc. (Germany), ViaCyte, Inc. (the US), Betalin Therapeutics Ltd (Israel), 4.NextCell Pharma AB (US), Kadimastem (Israel), Vertex Pharmaceuticals (US), Fresenius Medical Care AG & Co. KGaA (Germany), Sernava Corp (Canada), Novo Nordisk A/S (Denmark), and Generex Biotechnology (Canada).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Related:
Global Placental Stem Cell Therapy Market 2029
Global Nerve Repair and Regeneration Market: Market Segments: By Product (Neurostimulation and Neuromodulation Devices, Biomaterials); By Application (Neurostimulation and Neuromodulation Surgeries, Diagnostics, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy); By End User (Hospitals, Ambulatory Surgical Centers and Clinics); and Region – 2Analysis of Market Size, Share & Trends for 2014 – 22019 and Forecasts to 2030
Cell Therapy Technologies Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030
Table of Contents
TABLE OF CONTENT
CHAPTER 1. REPORT PROLOGUE
CHAPTER 2. MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
CHAPTER 3. RESEARCH METHODOLOGY
3.1 INTRODUCTION
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
CHAPTER 4. MARKET DYNAMICS
4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
4.4 CHALLENGES
4.5 MACROECONOMIC INDICATORS
4.6 TECHNOLOGY TRENDS & ASSESSMENT
CHAPTER 5. MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY
5.2 VALUE CHAIN ANALYSIS
5.3 INVESTMENT FEASIBILITY ANALYSIS
5.4 PRICING ANALYSIS
CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ALLOGENEIC
6.3 AUTOLOGOUS
CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION
7.1 INTRODUCTION
7.2 MEDICINE
7.3 CARDIOVASCULAR DISEASES
7.4 BONE REGENERATION
7.5 NEURODEGENERATIVE DISORDERS
7.6 WOUND HEALING
7.7 TREATMENT OF EYES
7.8 HEMATOPOIETIC DISORDERS
7.9 METABOLIC DISORDERS
7.10 CANCER
7.11 IMMUNODEFICIENCY
7.12 DIABETES
CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE
8.1 INTRODUCTION
8.2 ADIPOSE TISSUE
8.3 BONE MARROW
8.3 NEURAL
8.4 EMBRYO/CORD BLOOD-DERIVED
8.5 IPSCS
CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER
9.1 INTRODUCTION
9.2 BIOTECHNOLOGY COMPANIES
9.3 HOSPITALS & RESEARCH INSTITUTES
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.5 STEM CELL BANKS
CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION
10.1 INTRODUCTION
10.2 AMERICA
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 SOUTH AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 ITALY
10.3.1.4 SPAIN
10.3.1.5 UK
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 REPUBLIC OF KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 UNITED ARAB EMIRATES
10.5.2 SAUDI ARABIA
10.5.3 OMAN
10.5.4 KUWAIT
10.5.5 QATAR
10.5.6 REST OF THE MIDDLE EAST & AFRICA
CHAPTER 11. COMPANY LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS
11.3 KEY DEVELOPMENT & STRATEGIES
11.3.1 KEY DEVELOPMENTS
CHAPTER 12 COMPANY PROFILES
12.1 OSIRIS THERAPEUTICS, INC.
12.1.1 COMPANY OVERVIEW
12.1.2 PRODUCT TYPE OVERVIEW
12.1.3 FINANCIALS
12.2.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.2 MEDIPOST CO., LTD.
12.2.1 COMPANY OVERVIEW
12.2.2 PRODUCT TYPE OVERVIEW
12.2.3 FINANCIAL OVERVIEW
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.3 ANTEROGEN CO., LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 PRODUCT TYPE OVERVIEW
12.3.3 FINANCIAL OVERVIEW
12.3.4 KEY DEVELOPMENT
12.3.5 SWOT ANALYSIS
12.4 PHARMICELL CO., LTD.
12.4.1 COMPANY OVERVIEW
12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW
12.4.3 FINANCIAL OVERVIEW
12.4.4 KEY DEVELOPMENT
12.4.5 SWOT ANALYSIS
12.5 HOLOSTEM TERAPIE AVANZATE S.R.L.
12.5.1 COMPANY OVERVIEW
12.5.2 PRODUCT TYPE OVERVIEW
12.5.3 FINANCIAL OVERVIEW
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.6 JCR PHARMACEUTICALS CO., LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 PRODUCT TYPE OVERVIEW
12.6.3 FINANCIAL OVERVIEW
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.7 NUVASIVE, INC
12.7.1 OVERVIEW
12.7.2 PRODUCT TYPE OVERVIEW
12.7.3 FINANCIALS
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.8 RTI SURGICAL, INC.
12.8.1 OVERVIEW
12.8.2 PRODUCT TYPE OVERVIEW
12.8.3 FINANCIALS
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.9 ALLOSOURCE
12.9.1 OVERVIEW
12.9.2 PRODUCT TYPE OVERVIEW
12.9.3 FINANCIALS
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.10 THERMO FISHER SCIENTIFIC
12.10.1 OVERVIEW
12.10.2 PRODUCT TYPE OVERVIEW
12.10.3 FINANCIALS
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.11 OTHERS
CHAPTER 14 APPENDIX
